Search This Blog

Monday, May 1, 2023

Cantor Fitzgerald Maintains Pliant Therapeutics (PLRX) Overweight Recommendation

 Fintel reports that on May 1, 2023, Cantor Fitzgerald maintained coverage of Pliant Therapeutics (NASDAQ:PLRX) with a Overweight recommendation.

https://www.nasdaq.com/articles/cantor-fitzgerald-maintains-pliant-therapeutics-plrx-overweight-recommendation

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)